Browsing by Author "Thomas A"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    How can global guidelines support sustainable hygiene systems?
    (2023-Oct) Esteves Mills J; Thomas A; Abdalla N; El-Alam R; Al-Shabi K; Ashinyo ME; Bangoura FO; Charles K; Chipungu J; Cole AO; Engebretson B; Goyol K; Grasham CF; Grossi V; Hickling S; Kalandarov S; Ababu AK; Kholmuhammad K; Klaesener-Metzner N; Kugedera Z; Kwakye A; Lee-Llacer A; Maani PP; Makhafola B; Mohamed A; Monirul Alam M; Monse B; Northover H; Palomares A; Patabendi N; Paynter N; Prasad-Gautam O; Panthi SR; Rudge L; Saha S; Salaru I; Saltiel G; Sax L; Shahid MA; Gafur MS; Shrestha S; Szeberényi K; Tidwell JB; Trinies V; Yiha O; Ziganshin R; Gordon B; Cumming O; Water, Sanitation, Hygiene and Health Unit, Department of Environment, Climate Change and Health, World Health Organization (WHO), Geneva, Switzerland jestevesmills@gmail.com.; Ministry of Health, Government of Ethiopia, Addis Ababa, Ethiopia.; UNICEF Sri Lanka Country Office, Colombo, Sri Lanka.; University of Oxford, Oxford, UK.; Department of Public Health, Ministry of Health, Funafuti, Tuvalu.; World Vision International, Washington, District of Columbia, USA.; Ministry of Health & Social Protection, Government of Tajikistan, Dushanbe, Tajikistan.; WHO Ethiopia Country Office, Addis Ababa, Ethiopia.; WHO Country Office, Sana'a, Yemen.; Foreign Commonwealth & Development Office, Government of the United Kingdom, London, UK.; UNICEF Regional Office for East and Southern Africa, Nairobi, Kenya.; UNICEF Bangladesh Country Office, Dhaka, Bangladesh.; UNICEF Pakistan Country Office, Lahore, Pakistan.; IRC India, New Delhi, India.; Global Consultant, London, UK.; UNICEF Regional Office for South Asia, Kathmandu, Nepal.; WHO Bangladesh Country Office, Dhaka, Bangladesh.; WHO Iraq Country Office, Baghdad, Iraq.; Ministry of Health, Government of South Africa, Pretoria, South Africa.; UNICEF Nepal Country Office, Lalitpur, Nepal.; London School of Hygiene and Tropical Medicine, London, UK.; Global Handwashing Partnership, Washington, District of Columbia, USA.; Water, Sanitation, Hygiene and Health Unit, Department of Environment, Climate Change and Health, World Health Organization (WHO), Geneva, Switzerland.; World Bank, Washington, District of Columbia, USA.; Health Emergency Interventions, WHO, Geneva, Switzerland.; United Nations Children's Fund (UNICEF), New York, New York, USA.; Environmental Health, World Health Organization, Kathmandu, Nepal.; European Centre for Environment & Health, WHO Regional Office for Europe, Bonn, Germany.; Centre for Infectious Disease Research, Zambia (CIDRZ), Lusaka, Zambia.; WHO Regional Office for the Eastern Mediterranean, Amman, Jordan.; WaterAid, London, UK.; WHO Country Office, Conakry, Guinea.; Department of Public Health Engineering, Government of Bangladesh, Dhaka, Bangladesh.; National Center for Public Health, Government of Hungary, Budapest, Hungary.; WHO Tajikistan Country Office, Dushanbe, Tajikistan.; WHO Ghana Country Office, Accra, Ghana.; UNICEF Tajikistan Country Office, Dushanbe, Tajikistan.; UNICEF Ethiopia Country Office, Addis Ababa, Ethiopia.; National Agency for Public Health, Government of the Republic of Moldova, Chisinau, Moldova (the Republic of).; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.; German Agency for International Cooperation, Bonn, Germany.; Department of Health, Government of the Philippines, Manila, Philippines.; Department of Quality Assurance, Ghana Health Service, Accra, Ghana.
  • Thumbnail Image
    Item
    Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    (2016-Aug-30) Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK; European Vaccine Initiative, European Vaccine Initiative, Im Neuenheimer Feld 307, 69120, Heidelberg, Germany.; Center for Infectious Diseases Research in Zambia (CIDRZ), P.O. Box 34681, Lusaka, 10101, Zambia.; African Malaria Network Trust (AMANET), P.O. Box 33207, Dar Es Salaam, Tanzania.; Biomedical Primate Research Center (BPRC), P.O. Box 3306, 2280 GH, Rijswijk, The Netherlands.; Medical Research Council, P.O. Box 273, Banjul, The Gambia.; Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine and Dentistry, University of Sciences, Techniques and Technologies, Bamako, Mali. mthera@icermali.org.; Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine and Dentistry, University of Sciences, Techniques and Technologies, Bamako, Mali.
    BACKGROUND: The safety and immunogenicity of PfAMA1, adjuvanted with Alhydrogel(®) was assessed in malaria-experienced Malian adults. The malaria vaccine, PfAMA1-FVO [25-545] is a recombinant protein Pichia pastoris-expressed AMA-1 from Plasmodium falciparum FVO clone adsorbed to Alhydrogel(®), the control vaccine was tetanus toxoid produced from formaldehyde detoxified and purified tetanus toxin. METHODS: A double blind randomized controlled phase 1 study enrolled and followed 40 healthy adults aged 18-55 years in Bandiagara, Mali, West Africa, a rural setting with intense seasonal transmission of P. falciparum malaria. Volunteers were randomized to receive either 50 µg of malaria vaccine or the control vaccine. Three doses of vaccine were given on Days 0, 28 and 56, and participants were followed for 1 year. Solicited symptoms were assessed for seven days and unsolicited symptoms for 28 days after each vaccination. Serious adverse events were assessed throughout the study. The titres of anti-AMA-1 antibodies were measured by ELISA and P. falciparum growth inhibition assays were performed. RESULTS: Commonest local solicited adverse events were the injection site pain and swelling more frequent in the PfAMA1 group. No vaccine related serious adverse events were reported. A significant 3.5-fold increase of anti-AMA-1 IgG antibodies was observed in malaria vaccine recipients four weeks after the third immunization compared to the control group. CONCLUSION: The PfAMA1 showed a good safety profile. Most adverse events reported were of mild to moderate intensity. In addition, the vaccine induced a significant though short-lived increase in the anti-AMA1 IgG titres. Registered on www.clinicaltrials.gov with the number NCT00431808.